Focus on azithromycin
Loading...
Date
Authors
Padayachee, N.
Milne, M
Schellack, Natalie
Journal Title
Journal ISSN
Volume Title
Publisher
MedPharm Publications
Abstract
Azithromycin is a second-generation macrolide that was developed in the early 1980s as a semi-synthetic derivative of erythromycin. This broad-spectrum antibiotic is known for its activity against some Gram-negative organisms such as H. influenza. Azithromycin is similar to other macrolides, however, it also has the ability to inhibit quorum sensing and the formation of biofilm. Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine. The side-effect that needs to be monitored carefully is the risk of cardiotoxicity when azithromycin is combined with chloroquine or hydroxychloroquine.
Description
Keywords
Azithromycin, Antibacterial, Antiviral, Immunomodulatory, Chloroquine, Hydroxychloroquine, COVID-19 pandemic, Coronavirus disease 2019 (COVID-19), Influenza, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Sustainable Development Goals
Citation
Padayachee, N., Milne, M. & Schellack, N., 2021. Focus on azithromycin. South African General Practitioner, 2(1), pp. 6-8, doi: 10.36303/SAGP.2021.2.1.0059.
